Generic drugmaker Watson Pharmaceuticals Inc said U.S. health regulators approved its copycat version of ViroPharma Inc's antibiotic Vancocin.
Separately, ViroPharma said the U.S. Food and Drug Administration declined its citizen petition, which was filed to prevent Watson from launching the generic version.
Shares of ViroPharma were trading down 18 percent at $23.40 in premarket.
Watson said it has started shipping the drug, which recorded sales of $332 million for the 12 months ended February 29, 2012.
ViroPharma shares closed at $28.61 on Monday on the Nasdaq.
(Reporting by Anand Basu in Bangalore; Editing by Sriraj Kalluvila)
Trending On Reuters
South Korea declared on Tuesday it is effectively out of danger from Middle East Respiratory Syndrome (MERS), more than two months after the first case was reported and began spreading in hospital settings to kill 36 people. Full Article
Maruti Suzuki June-quarter profit jumps 56 percent; lower costs, higher sales. Full Article
Florida family finds $1 million in treasure from sunken Spanish armada. Full Article